FIG 2.
AZ-27 targeting RSV replication. (A) Comparison of the AZ-27 and fusion inhibitor AZD4316 activities in a time-of-addition study. EC50s were measured by RSV ELISA in HEp-2 cells following a 3-day infection by RSV A2 at an MOI of 0.02 with compounds added before (−2 h) or after (+6 to 24 h) the infection. Data are means ± standard deviations from triplicates of a representative experiment with EC50s of >50 μM depicted as 50 μM. (B) Inhibition of BHK-21 cell-based RSV replicon following 2-day AZ-27 treatment in a representative replicon luciferase assay. Mean replicon luciferase signals ± standard deviations from triplicates are depicted. (C) Inhibition of HeLa cell-based RSV replicon following 2-day AZ-27 treatment as visualized by microscopy of the replicon GFP reporter expression.